Preclinical News and Research

RSS

Provectus to begin clinical trials of new cancer treatment, PV-10

Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.

21 Jul 2005

Role of IL-24 in regulating the immune system

Researchers at Introgen Therapeutics and their collaborators at The University of Texas M. D. Anderson Cancer Center have published new findings on the role of IL-24 in regulating the immune system in the current online issue of the Journal of Leukocyte Biology.

21 Jul 2005

New design for HIV vaccine trials in animals

Emory University researchers have proposed a new design for HIV vaccine trials in animals that would more closely mimic how humans are exposed to the virus - potentially giving AIDS researchers a more effective tool in developing successful treatments to prevent HIV infection.

20 Jul 2005

Potential use of NH neurotransmitters as novel source for psychiatric drugs

Physiologists and medical researchers have long recognized the important endocrine roles played by the pituitary hormones oxytocin (OT) and vasopressin (VP) on peripheral systems in lactation, uterine contraction and urine concentration.

19 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Tool to predict potential ovarian failure after radiation

Doctors in the United Kingdom have created a table to predict when a woman who has undergone radiation therapy as a part of cancer treatment regimen in her abdominal or pelvic area may become sterile

6 Jul 2005

Doctors are able to predict sterility in women following radiation treatment for cancer

Doctors in the United Kingdom have created a table to predict when a woman who has undergone radiation therapy as a part of cancer treatment regimen in her abdominal or pelvic area may become sterile, according to a new study.

4 Jul 2005

New drug to treat stroke complications tested in US for the first time as part of an international trial

A Roanoke, Va. woman is the first U. S. participant in an international, multi center trial of a new drug that shows promise in treating complications from a stroke.

1 Jul 2005

Preclinical data suggest CuraGen's Velafermin may protect the gastrointestinal tract and decrease associated toxicity following exposure to radiation

New preclinical data on velafermin (CG53135), CuraGen's Phase II clinical product being developed for the prevention of oral mucositis (OM), suggesting that velafermin may protect the gastrointestinal tract and decrease associated toxicity, including enteritis and diarrhea, following exposure to radiation.

1 Jul 2005

Tetracycline antibiotic shows promise for treating osteoarthritis

A tetracycline antibiotic, doxycycline, has been successfully used to treat a wide-range of bacterial infections. In addition to its effects as an antibiotic, doxycycline has other actions as a drug and, in laboratory studies with animals and with human tissue, can inhibit the degradation of cartilage in a way that could be useful for the treatment of osteoarthritis (OA).

28 Jun 2005

Metabasis and Merck collaborate to develop new treatment for diabetes, hyperlipidemia and obesity

Metabasis Therapeutics and Merck announced today that they have formed a collaboration to research, develop and commercialize novel small molecule therapeutics with potential to treat several diseases, including type II diabetes, hyperlipidemia and obesity, by activation of an enzyme in the liver called AMP-activated Protein Kinase (AMPK).

27 Jun 2005

Partnership to develop an AIDS vaccine using a promising new technology

GlaxoSmithKline Biologicals (GSK Biologicals) and the International AIDS Vaccine Initiative (IAVI) today announced a public-private partnership to develop an AIDS vaccine using a promising new technology.

21 Jun 2005

New cardiovascular drug derived from Dan Shen (Saliva miltiorrhiza)

Through a large number of clinical trials over the past 3 years, researchers from the CAS Shanghai Institute of Materia Medica (SIMM) have developed a new cardiovascular drug with a definite effective component extracted from Dan Shen (Saliva miltiorrhiza), a medicinal herb widely used in China.

21 Jun 2005

Promising new tuberculosis drug enters clinical trial

A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced this week.

15 Jun 2005

Non-profit public-private partnership develops affordable, new drug regimens for tuberculosis

The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.

14 Jun 2005

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005

Venom of marine cone snails may provide an improved treatment for neuropathic pain associated with diabetes

A cone snail toxin discovered by Melbourne researchers has proven to have great potential for easing pain and could provide an improved treatment for neuropathic pain associated with diabetes.

12 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection.

7 Jun 2005

Genetically engineered virus has shown promise as a treatment for patients with colorectal cancer

A single injection of a genetically engineered virus has shown promise as a treatment for patients with colorectal cancer that has spread to the liver, according to preliminary results reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

6 Jun 2005